The singer followed his successful Buenos Aires run with two São Paulo concerts that blasted through the barriers between ...
Explore the benefits of the Precision GLP-1 agonist, a new therapy that improves glycaemic control and reduces side effects.
Q4 2025 earnings call recap: 2026 revenue/EBITDA/EPS guidance, CREXONT growth, biosimilars & GLP-1 updates—read key takeaways.
"Dosing the first patient in Phase III represents a major milestone for MDR-001 and for AI-enabled drug development," said Zhangming Niu, Founder and Chief Executive Officer of MindRank. "We believe ...
It’s estimated that about one in 10 Americans have taken a GLP‑1 weight‑loss drug, and demand is surging. Ads are everywhere, but so are concerns about safety, cost and ...
So the AMA, I think, formally recognized obesity as a disease back in 2013, and this was really important in terms of legitimizing what clinicians and patients already, really already were ...
GLP-1 drugs like Ozempic aren't just suppressing appetite — they may be rewiring the brain's reward system, and patients are spontaneously picking up hobbies, quitting alcohol, and signing up for 5Ks ...
GLP-1 drugs aren't just suppressing appetite — neuroscientists believe they're restoring a broken motivation pathway that may ...
Bilingual telehealth provider MiSalud Health today announced a $25/month all-inclusive GLP-1 support program. Its goal is to ...
The Allspring Premier Large Company Growth Fund lagged its benchmark in Q4 2025 despite gains from Natera. Read the full analysis for more details.
Protein dominates Natural Products Expo West 2026, but brands must prove they can deliver on taste, texture and next-gen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results